Check for updates

Received: 10 December 2021 | Revised: 15 February 2022 | Accepted: 22 February 2022

DOI: 10.1002/ijc.34018

CANCER THERAPY AND PREVENTION

IJC INTERNATIONAL JOURNAL of CANCER

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)

Nicholas D. James[1] | Noel W. Clarke[2] | Adrian Cook[3] | Adnan Ali[4] | Alex P. Hoyle[5] | Gerhardt Attard[6] | Christopher D. Brawley[3] | Simon Chowdhury[7] | William R. Cross[8] | David P. Dearnaley[9] | Johann S. de Bono[1] | Carlos Diaz-Montana[3] | Duncan Gilbert[3] | Silke Gillessen[10] | Clare Gilson[3,11] | Rob J. Jones[12] | Ruth E. Langley[3] | Zafar I. Malik[13] | David J. Matheson[14] | Robin Millman[15] | Chris C. Parker[16] | Cheryl Pugh[3] | Hannah Rush[3,17] | J. Martin Russell[18,19] | Dominik R. Berthold[20] | Michelle L. Buckner[3] | Malcolm D. Mason[21] | Alastair W. S. Ritchie[22] | Alison J. Birtle[23] | Susannah J. Brock[24] | Prantik Das[25] | Dan Ford[26] | Joanna Gale[27] | Warren Grant[28] | Emma K. Gray[29] | Peter Hoskin[30] | Mohammad M. Khan[31,32] | Caroline Manetta[33] | Neil J. McPhail[34] | Joe M. O'Sullivan[35] | Omi Parikh[36] | Carla Perna[37] | Carmel J. Pezaro[38] | Andrew S. Protheroe[39] | Angus J. Robinson[40] | Sarah M. Rudman[17] | Denise J. Sheehan[41] | Narayanan N. Srihari[42] | Isabel Syndikus[13] | Jacob S. Tanguay[43] | Carys W. Thomas[44] | Salil Vengalil[45] | John Wagstaff[46] | James P. Wylie[4] | Mahesh K. B. Parmar[3] | Matthew R. Sydes[3] | for the STAMPEDE Trials Collaborative Group

[1]Institute of Cancer Research, London, UK

[2]The Departments of Surgery & Urology, The Christie & Salford Royal Hospitals, Manchester, UK

[3]MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK

[4]The Christie NHS Foundation Trust, Manchester, UK

[5]Salford Royal HS Foundation Trust, Manchester, UK

Abbreviations: AA, abiraterone acetate; AAP, abiraterone acetate + prednisone/prednisolone; ADT, androgen deprivation therapy; BP, blood pressure; CI, confidence interval; CRUK, Cancer Research UK; CT, computerised tomography (as in CT scan); CTCAE, Common Terminology Criteria for Adverse Events; CTU, clinical trials unit; FFS, failure-free survival; GnRH, gonadotrophin-releasing hormone; HR, hazard ratio; IQR, interquartile range; mg, milligrams; MRC, Medical Research Council; MRI, magnetic resonance imaging; NHS, National Health Service; NIHR, National Institute of Health Research; NSAID, nonsteroidal antiinflammatory drug; PSA, prostate-specific antigen; QOL, quality of life; SAKK, Swiss Group for Clinical Cancer Research; SOC, standard-of-care; SOC + AAP, standard-of-care plus abiraterone acetate + prednisone/prednisolone; UCL, University College London; UK, United Kingdom; WHO, World Health Organisation.

Mahesh K. B. Parmar and Matthew R. Sydes contributed equally to our study.

Conference presentation: Preliminary data underpinning this article were presented at the European Society of Medical Oncology 2020: https://doi.org/10.1016/j.annonc.2020.08.871.

[Correction added on 6 June 2022, after first online publication - text for subgroup did not match table: Figure 2 and Figure 3 captions have been amended to better clarify the content; "for the STAMPEDE Trials Collaborative Group" has been added at the end of the author group.]

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2022 The Authors. *International Journal of Cancer* published by John Wiley & Sons Ltd on behalf of UICC.

13. Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. *Ann Oncol*. 2018;29:1235-1248.
14. Rush HL, Murphy L, Morgans AK, et al. Quality of life for men with prostate cancer contemporaneously randomly allocated to receive either docetaxel or abiraterone in the STAMPEDE trial. *J Clin Oncol*. 2021;40:825-836.
15. Parker CC, James ND, Brawley CD, et al. Systemic therapy for advanced or metastatic prostate cancer: evaluation of drug efficacy i. radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. *Lancet*. 2018;392:2353-2366.
16. Attard G, Murphy L, Clarke NW, et al. Systemic therapy in advancing or metastatic prostate cancer: evaluation of drug efficacy i. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. *Lancet*. 2022;399:447-460.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: James ND, Clarke NW, Cook A, et al. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). *Int J Cancer*. 2022;151(3):422-434. doi:10.1002/ijc.34018